$29.58
-0.39-1.30%
Last update: 11:49 AM
15 minutes delayed
Comments
Loading...
Pfizer
PFENYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Pfizer (NYSE:PFE) Stock, Analyst Ratings, Price Targets, Forecasts
Pfizer Inc has a consensus price target of $41.96 based on the ratings of 24 analysts. The high is $60 issued by Goldman Sachs on December 13, 2022. The low is $27 issued by UBS on December 14, 2023. The 3 most-recent analyst ratings were released by Barclays, Cantor Fitzgerald, and Cantor Fitzgerald on July 10, 2024, July 10, 2024, and July 1, 2024, respectively. With an average price target of $40 between Barclays, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 35.23% upside for Pfizer Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Cantor Fitzgerald
Morgan Stanley
BMO Capital
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Pfizer
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 1.42% | Barclays | Carter Gould | $28 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/10/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 07/01/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 05/02/2024 | Buy Now | -1.96% | Morgan Stanley | Terence Flynn | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 05/02/2024 | Buy Now | 21.7% | BMO Capital | Evan David Seigerman | $33 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 04/18/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/15/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
| 03/04/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 21.7% | Guggenheim | Vamil Divan | → $36 | Initiates | → Buy | Get Alert |
| 01/31/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | Buy Now | 52.13% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/04/2024 | Buy Now | 8.18% | TD Cowen | Steve Scala | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/14/2023 | Buy Now | 21.7% | Truist Securities | Robyn Karnauskas | $42 → $36 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | -8.72% | UBS | Colin Bristow | $34 → $27 | Maintains | Neutral | Get Alert |
| 12/14/2023 | Buy Now | -5.34% | Barclays | Carter Gould | $34 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/04/2023 | Buy Now | 41.99% | Truist Securities | Robyn Karnauskas | → $42 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 11/01/2023 | Buy Now | 14.94% | Barclays | Carter Gould | $35 → $34 | Maintains | Equal-Weight | Get Alert |
| 11/01/2023 | Buy Now | 25.08% | Morgan Stanley | Terence Flynn | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 10/20/2023 | Buy Now | 14.94% | UBS | Colin Bristow | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
| 10/17/2023 | Buy Now | 41.99% | Truist Securities | Robyn Karnauskas | $62 → $42 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 31.85% | Morgan Stanley | Terence Flynn | $40 → $39 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 18.32% | Wells Fargo | Mohit Bansal | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 11.56% | BMO Capital | Evan David Seigerman | $44 → $33 | Maintains | Outperform | Get Alert |
| 10/16/2023 | Buy Now | 18.32% | Citigroup | Andrew Baum | $42 → $35 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 14.94% | JP Morgan | Chris Schott | $36 → $34 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 18.32% | Wells Fargo | Mohit Bansal | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 31.85% | Jefferies | Akash Tewari | $38 → $39 | Upgrade | Hold → Buy | Get Alert |
| 10/06/2023 | Buy Now | 21.7% | JP Morgan | Chris Schott | $39 → $36 | Maintains | Neutral | Get Alert |
| 10/02/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 109.6% | Truist Securities | Robyn Karnauskas | → $62 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/30/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | 109.6% | Truist Securities | Robyn Karnauskas | $64 → $62 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 35.23% | Morgan Stanley | Terence Flynn | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | 48.75% | BMO Capital | Evan David Seigerman | $45 → $44 | Maintains | Outperform | Get Alert |
| 07/21/2023 | Buy Now | 41.99% | Morgan Stanley | Terence Flynn | $43 → $42 | Maintains | Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 69.03% | HSBC | Rajesh Kumar | → $50 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | 45.37% | Morgan Stanley | Terence Flynn | $43 → $43 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | Buy Now | 28.47% | Barclays | Carter Gould | $40 → $38 | Maintains | Equal-Weight | Get Alert |
| 06/29/2023 | Buy Now | 35.23% | Credit Suisse | Trung Huynh | $47 → $40 | Downgrade | Outperform → Neutral | Get Alert |
| 06/23/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/11/2023 | Buy Now | 28.47% | Daiwa Capital | Narumi Nakagiri | → $38 | Downgrade | Outperform → Neutral | Get Alert |
| 05/03/2023 | Buy Now | 58.89% | Credit Suisse | Trung Huynh | $50 → $47 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | 35.23% | Barclays | Carter Gould | $43 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/21/2023 | Buy Now | 52.13% | B of A Securities | Geoff Meacham | $50 → $45 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | 45.37% | Barclays | Carter Gould | $44 → $43 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | 48.75% | Morgan Stanley | Terence Flynn | $45 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/17/2023 | Buy Now | 48.75% | Wells Fargo | Mohit Bansal | $50 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 45.37% | Jefferies | Akash Tewari | → $43 | Initiates | → Hold | Get Alert |
| 02/07/2023 | Buy Now | 72.41% | Daiwa Capital | Narumi Nakagiri | → $51 | Upgrade | Neutral → Outperform | Get Alert |
| 02/01/2023 | Buy Now | 52.13% | Morgan Stanley | Terence Flynn | $53 → $45 | Maintains | Equal-Weight | Get Alert |
| 02/01/2023 | Buy Now | 153.55% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | → Overweight | Get Alert |
| 02/01/2023 | Buy Now | 69.03% | Credit Suisse | Trung Huynh | $54 → $50 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 79.18% | BMO Capital | Evan David Seigerman | $55 → $53 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 48.75% | Barclays | Carter Gould | $49 → $44 | Maintains | Equal-Weight | Get Alert |
| 02/01/2023 | Buy Now | 55.51% | Atlantic Equities | Steve Chesney | $50 → $46 | Maintains | Neutral | Get Alert |
| 02/01/2023 | Buy Now | 62.27% | SVB Leerink | David Risinger | $49 → $48 | Maintains | Market Perform | Get Alert |
| 01/26/2023 | Buy Now | 58.89% | UBS | Colin Bristow | $55 → $47 | Downgrade | Buy → Neutral | Get Alert |
| 01/17/2023 | Buy Now | 69.03% | Wells Fargo | Mohit Bansal | $54 → $50 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/04/2023 | Buy Now | 102.84% | B of A Securities | Geoff Meacham | → $60 | Downgrade | Buy → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 79.18% | Morgan Stanley | Terence Flynn | $51 → $53 | Maintains | Equal-Weight | Get Alert |
| 12/13/2022 | Buy Now | 102.84% | Goldman Sachs | Chris Shibutani | $47 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 11/18/2022 | Buy Now | 85.94% | Credit Suisse | Trung Huynh | → $55 | Initiates | → Outperform | Get Alert |
| 11/03/2022 | Buy Now | 65.65% | SVB Leerink | David Risinger | $48 → $49 | Maintains | Market Perform | Get Alert |
| 11/02/2022 | Buy Now | 82.56% | Wells Fargo | Mohit Bansal | $55 → $54 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 65.65% | Barclays | Carter Gould | $44 → $49 | Maintains | Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | 72.41% | Morgan Stanley | Terence Flynn | $50 → $51 | Maintains | Equal-Weight | Get Alert |
| 10/12/2022 | Buy Now | 69.03% | Morgan Stanley | Terence Flynn | $49 → $50 | Maintains | Equal-Weight | Get Alert |
| 10/12/2022 | Buy Now | 48.75% | Barclays | Carter Gould | $50 → $44 | Maintains | Equal-Weight | Get Alert |
| 10/11/2022 | Buy Now | 62.27% | SVB Leerink | David Risinger | $53 → $48 | Maintains | Market Perform | Get Alert |
| 08/01/2022 | Buy Now | 75.8% | Barclays | Carter Gould | $50 → $52 | Maintains | Equal-Weight | Get Alert |
| 07/29/2022 | Buy Now | 79.18% | SVB Leerink | David Risinger | $55 → $53 | Maintains | Market Perform | Get Alert |
| 07/08/2022 | Buy Now | 65.65% | Morgan Stanley | Terence Flynn | $52 → $49 | Maintains | Equal-Weight | Get Alert |
| 05/04/2022 | Buy Now | 75.8% | Morgan Stanley | Matthew Harrison | $55 → $52 | Maintains | Equal-Weight | Get Alert |
| 05/04/2022 | Buy Now | 85.94% | Wells Fargo | Mohit Bansal | $60 → $55 | Maintains | Overweight | Get Alert |
| 04/05/2022 | Buy Now | 92.7% | Citigroup | Andrew Baum | $46 → $57 | Maintains | Neutral | Get Alert |
| 02/10/2022 | Buy Now | 85.94% | Morgan Stanley | Matthew Harrison | $60 → $55 | Maintains | Equal-Weight | Get Alert |
| 01/07/2022 | Buy Now | 119.74% | Wells Fargo | Mohit Bansal | $60 → $65 | Maintains | Overweight | Get Alert |
| 01/05/2022 | Buy Now | 136.65% | B of A Securities | Geoff Meacham | $59 → $70 | Upgrade | Neutral → Buy | Get Alert |
| 12/17/2021 | Buy Now | 72.41% | Goldman Sachs | Chris Shibutani | — | Initiates | → Neutral | Get Alert |
| 12/15/2021 | Buy Now | 89.32% | SVB Leerink | Geoffrey Porges | — | Maintains | Market Perform | Get Alert |
| 12/14/2021 | Buy Now | 89.32% | Mizuho | Vamil Divan | — | Maintains | Neutral | Get Alert |
| 12/13/2021 | Buy Now | 102.84% | UBS | Colin Bristow | — | Upgrade | Neutral → Buy | Get Alert |
| 12/10/2021 | Buy Now | 82.56% | Barclays | Carter Gould | — | Maintains | Equal-Weight | Get Alert |
| 12/09/2021 | Buy Now | 102.84% | Wells Fargo | Mohit Bansal | — | Initiates | → Overweight | Get Alert |
| 11/29/2021 | Buy Now | 102.84% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 11/19/2021 | Buy Now | 102.84% | BMO Capital | Evan Seigerman | — | Initiates | → Outperform | Get Alert |
| 11/03/2021 | Buy Now | 62.27% | SVB Leerink | Geoffrey Porges | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Pfizer (PFE) stock?
The latest price target for Pfizer (NYSE:PFE) was reported by Barclays on July 10, 2024. The analyst firm set a price target for $30.00 expecting PFE to rise to within 12 months (a possible 1.42% upside). 45 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pfizer (PFE)?
The latest analyst rating for Pfizer (NYSE:PFE) was provided by Barclays, and Pfizer maintained their equal-weight rating.
When was the last upgrade for Pfizer (PFE)?
The last upgrade for Pfizer Inc happened on October 16, 2023 when Jefferies raised their price target to $39. Jefferies previously had a hold for Pfizer Inc.
When was the last downgrade for Pfizer (PFE)?
The last downgrade for Pfizer Inc happened on March 22, 2024 when Argus Research changed their price target from N/A to N/A for Pfizer Inc.
When is the next analyst rating going to be posted or updated for Pfizer (PFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Pfizer (PFE) correct?
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a maintained with a price target of $28.00 to $30.00. The current price Pfizer (PFE) is trading at is $29.58, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.